Raleigh, NC, United States of America

Suzanne Dagher

USPTO Granted Patents = 6 

 

Average Co-Inventor Count = 2.3

ph-index = 3

Forward Citations = 20(Granted Patents)


Location History:

  • Durham, NC (US) (2010)
  • Dearborn, MI (US) (2017 - 2019)
  • Raleigh, NC (US) (2015 - 2024)

Company Filing History:


Years Active: 2010-2024

Loading Chart...
Loading Chart...
6 patents (USPTO):Explore Patents

Title: Innovator Spotlight: Suzanne Dagher Revolutionizing the Biotech Industry

Introduction: Suzanne Dagher, a talented inventor based in Raleigh, NC, has made significant contributions to the biotechnology field. With an impressive portfolio of 6 patents, Dagher's innovative work has paved the way for groundbreaking advancements in the industry.

Latest Patents: Among Suzanne Dagher's latest patents is the invention of novel recombinant forms of β-hexosyl-transferases (BHT) and their uses in producing galacto-oligosaccharides (GOS) or as food additives. This cutting-edge technology has the potential to transform the way food products are developed and produced.

Career Highlights: Suzanne Dagher has been a key figure in companies such as Phasebio Pharmaceuticals, Inc. and North Carolina State University. His expertise and innovative mindset have driven these organizations towards success in the biotech sector. Dagher's collaborative approach and commitment to excellence have been instrumental in his career achievements.

Collaborations: Throughout his career, Suzanne Dagher has collaborated with esteemed professionals in the field, including Jose M Bruno-Barcena and Maria Azcarate-Peril. These partnerships have led to the development of groundbreaking technologies and solutions that have had a lasting impact on the biotech industry.

Conclusion: Suzanne Dagher's inventive spirit and dedication to advancing biotechnology have solidified his reputation as a trailblazer in the field. His groundbreaking patents and successful collaborations serve as a testament to his commitment to driving innovation and shaping the future of the biotech industry.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…